No Data
No Data
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
SA Asks: Which Big Pharmas Would Be Most Impacted by Higher Tariffs?
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Express News | Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus Biosciences: Promising Phase 2 Data and Strategic Valuation Drive Buy Rating